Business Wire

FL-EXSCIENTIA

15.3.2023 12:01:37 CET | Business Wire | Press release

Share
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR

Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023, at the Orange County Convention Center in Orlando, FL. These abstracts highlight the components of Exscientia's approach to precision discovery, design and personalised medicine as well as planned innovation in the clinic.

“The clinical and preclinical data showcased at AACR further validate Exscientia's functional precision medicine platform and translational research capabilities,” said Andrew Hopkins, D.Phil, founder and Chief Executive Officer of Exscientia. “These new data demonstrate the potential of integrating outstanding science with cutting-edge AI, to efficiently identify novel targets with the potential for increased probability of clinical success. We also believe that our platform can be used to predict outcomes that help identify cancer patients with high unmet need who may benefit most from treatment. We look forward to advancing these programmes and expanding our pipeline with the goal of developing precision-designed, truly personalised medicines for patients around the world.”

Abstracts Accepted for Poster Presentation:

Title: Identification of transcript adenosine fingerprint to enrich for A2AR and PD-1 inhibition responders
Session Title: Biomarkers of Therapeutic Benefit 2
Abstract Number: #2151
Date/Time: Monday, April 17 / 9:00 AM - 12:30 PM EDT

Next generation precision cancer medicine mandates a deep understanding of the disease milieu and drug function to create complex patient selection biomarkers, more than single mutations. To enrich for patients who will most likely respond to EXS21546 (‘546), Exscientia's clinical stage A2AR-selective antagonist targeting the adenosine pathway, Exscientia researchers leveraged a combination of single cell functional and transcriptomics from complex primary patient samples to identify an adenosine-induced immunosuppression biomarker signature (adenosine burden score or ABS). The ABS correlates with checkpoint inhibitor (CI) response prediction to potentially predict patients likely to benefit from combined A2AR antagonism and CI. Here, researchers show that the adenosine burden, as monitored by ABS, is reduced following antagonism of A2AR with ‘546, which in turn restores CI response potential. The ABS is being confirmed retrospectively in the ongoing IGNITE Phase 1/2 clinical study of ‘546 in combination with a PD-1 inhibitor in relapsed/refractory renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC).

Title: Characterizing antitumor responses to EXS74539, a novel, reversible LSD1 inhibitor with potential in small-cell lung cancer
Session Title: Epigenetics
Abstract Number: #6290
Date/Time: Wednesday, April 19 / 9:00 AM - 12:30 PM EDT

LSD1 is an epigenetic target with critical roles in oncology, notably demethylating histones and other proteins, thereby suppressing the expression of genes required for cellular differentiation. Historically, LSD1 inhibitors in development have been unable to achieve the combination of appropriate pharmacokinetics, good brain penetrance and a reversible mechanism of action. By leveraging generative design algorithms and active learning, Exscientia designed a highly differentiated LSD1 inhibitor, EXS74539 (‘539). ‘539 is a potent, selective and reversible brain-penetrant molecule, combining the potential to treat tumours and metastases in the brain with potential clinical safety benefits through reversible inhibition of LSD1. ‘539 is currently in IND-enabling studies as a potential treatment across oncology and haematology. Preclinical data has shown that ‘539 has potent anti-proliferative activity in in vitro models of small cell lung cancer (SCLC), with anti-tumour activity observed in selected SCLC xenograft tumour-bearing mice.

Title: Discovering novel targetable pathways by combining functional and multi-omic data from primary ovarian cancer samples
Session Title: Novel Targets and Pathways
Abstract Number: #4956
Date/Time: Tuesday, April 18 / 1:30 PM - 5:00 PM EDT

Mapping and interpreting single cell functional and multi-omics data at baseline and after perturbation of complex primary model systems reveals a previously unexplored convergent putative target landscape that Exscientia is further validating as potential next-generation anticancer nodes. The high unmet medical need in indications such as high grade serous ovarian cancer (HGSOC) drives a requirement for innovation to uncover novel targets. Standard target discovery processes that often heavily rely upfront on outgrown cell line models with well-averaged readouts have hindered approval rates for drugs entering trials. This study highlights ongoing work using Exscientia's precision medicine platform in combination with proprietary methodology for multi-omics and multi-modal dataset mapping which could have the potential to improve patient outcomes by uncovering clinical relevance at the target discovery stage. Here, researchers report a novel way of uncovering several high confidence convergent putative targets, seemingly overlooked in cell line studies. By mechanistically characterising one such functional sensitivity node, ALK/FAK1/IGF1R, the study reveals tumour necrosis factor (TNF) via the nuclear factor kappa B (NFкB) pathway as a promising focus area for HGSOC via the evaluation of malignant pleural effusion and ascites from patients with late stage ovarian cancer.

Title: Data from first-in-human study of EXS21546, an A2A receptor antagonist, now progressing into Phase 1 in RCC/NSCLC
Session Title: Phase I Clinical Trials in Progress
Abstract Number: #CT114
Date/Time: Monday, April 17 / 1:30 PM - 5:00 PM EDT

Pharmacokinetics, pharmacodynamics, safety and tolerability of EXS21546 were confirmed in a healthy volunteer study, allowing selection of a starting dose for the ongoing IGNITE Phase 1/2 study ​​in combination with a PD-1 inhibitor in relapsed/refractory RCC and NSCLC. The IGNITE trial design was based on extensive simulations to enable the most efficient continuous reassessment method settings, and will allow further verification of the patient enrichment biomarker strategy (adenosine burden score or ABS).

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Exscientia Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to Exscientia’s plans to present at AACR, the progress of discovery and development of candidate molecules, and the timing and progress of, and data reported from, pre-clinical studies and clinical trials of Exscientia’s product candidates. Any statement describing Exscientia’s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and other factors. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgement of its management, these statements are based only on facts and factors currently known by the Company at the time of this press release. As a result, you are cautioned not to rely on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005285/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release

Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release

Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release

Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req

From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release

The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye